6-K
File 001-15170
CABOTEGRAVIR LA FOR PREP RECEIVES POSITIVE CHMP
- Filing date
- 24 Jul 2023
- Reporting date
- 24 Jul 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
GSK plc reports
- Company location
- London
GSK plc has filed 6,794 SEC EDGAR filings since 12 Jan 2001
SEC filing history
Showing 776-800 of 1,000 matching filings.
Per page
25
Current page
32
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 20 Jul 2023
- Reporting date
- 20 Jul 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SC 13D/A
AMENDMENT TO FORM SC 13D
- Filing date
- 20 Jul 2023
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 17 Jul 2023
- Reporting date
- 17 Jul 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 13 Jul 2023
- Reporting date
- 13 Jul 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TOTAL VOTING RIGHTS
- Filing date
- 03 Jul 2023
- Reporting date
- 03 Jul 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK COMPLETES ACQUISITION OF BELLUS HEALTH
- Filing date
- 28 Jun 2023
- Reporting date
- 28 Jun 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
FDA FAST TRACK FOR GONORRHOEA VACCINE CANDIDATE
- Filing date
- 27 Jun 2023
- Reporting date
- 27 Jun 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK DAPRODUSTAT GAINS POSITIVE EMA CHMP OPINION
- Filing date
- 26 Jun 2023
- Reporting date
- 26 Jun 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
SHINGRIX APPROVED IN JAPAN FOR ADULTS 18 AND OVER
- Filing date
- 26 Jun 2023
- Reporting date
- 26 Jun 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 23 Jun 2023
- Reporting date
- 23 Jun 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 23 Jun 2023
- Reporting date
- 23 Jun 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 23 Jun 2023
- Reporting date
- 23 Jun 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
STATEMENT: ZANTAC (RANITIDINE) LITIGATION
- Filing date
- 23 Jun 2023
- Reporting date
- 23 Jun 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSKS AREXVY RECOMMENDED BY ACIP
- Filing date
- 22 Jun 2023
- Reporting date
- 22 Jun 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
11-K
File 001-15170
ANNUAL REPORT
- Filing date
- 21 Jun 2023
- Reporting date
- 31 Dec 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
11-K
File 001-15170
ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE
- Filing date
- 21 Jun 2023
- Reporting date
- 31 Dec 2022
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
SEASON TWO DATA FOR GSK AREXVY RSV OA VACCINE
- Filing date
- 21 Jun 2023
- Reporting date
- 21 Jun 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
EXTENSION OF FDA REVIEW PERIOD FOR MOMELOTINIB
- Filing date
- 16 Jun 2023
- Reporting date
- 16 Jun 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 12 Jun 2023
- Reporting date
- 12 Jun 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
EU AUTHORISATION OF GSKS RSV VACCINE AREXVY
- Filing date
- 07 Jun 2023
- Reporting date
- 07 Jun 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK RECEIVES US FDA FILE ACCEPTANCE FOR JEMPERLI
- Filing date
- 06 Jun 2023
- Reporting date
- 06 Jun 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TOTAL VOTING RIGHTS
- Filing date
- 01 Jun 2023
- Reporting date
- 01 Jun 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SD
File 001-15170
SPECIALIZED DISCLOSURE
- Filing date
- 30 May 2023
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 22 May 2023
- Reporting date
- 22 May 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing